- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02474719
Transfer and Ultrafiltration In Peritoneal Dialysis (TULIPE)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Franche-Comté
-
Besançon, Franche-Comté, France, 25000
- Besançon University Hospital, Nephrology Department
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients hospitalized in the Nephrology department of the Besançon University Hospital
- Patients treated by continuous ambulatory peritoneal dialysis or ambulatory peritoneal dialysis for at least 6 months
- Absence of hospitalization caused by an infection in the month prior to inclusion
- Patients with a ratio (D / P) of the concentration of creatinine in the blood and dialysate between 0.5 and 0.8 on a checkup of less than 1 year.
- No contraindication to the use of hypertonic bag
- Signature of informed consent for participation indicating that the subject has understood the purpose and procedures required by the study and agrees to participate in the study and comply with the requirements and limitations inherent in this study
- Affiliation to a French social security system or beneficiary
Exclusion Criteria:
- Legal incapacity or limited legal capacity
- Patients unlikely to cooperate in the study and/or low cooperation anticipated by the investigator
- Patients without health insurance
- Pregnant women
- Patient being in the exclusion period from another study or planned by the "national register of volunteers"
- Hospitalization caused by an infection in the month prior to inclusion
- Patients with a peritoneal dialysis catheter dysfunction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: conventional scheme followed by alternate schem
The first day of the study, patients receive an adapted conventional peritoneal dialysis scheme: 2 cycles of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 2 cycles of purification (stasis: 110 mn ; volume 1200cc/m²). The second day, patients receive an adapted and alternate scheme: 1 cycle of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 1 cycle of purification (stasis: 110 mn ; volume 1200cc/m²), the two cycles being repeated once. |
Dialysate samples (8 by scheme, volume of 10 mL) are collected at each cycle (one at the beginning and one at the end of the cycle).
A blood sample (5 mL) is collected at the beginning of the second scheme and a 24-hour urine sample at the end of the second scheme.
|
|
Experimental: alternate scheme followed by conventional scheme
The first day of the study, patients receive an adapted and alternate peritoneal dialysis scheme: 1 cycle of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 1 cycle of purification (stasis: 110 mn ; volume 1200cc/m²), the two cycles being repeated once. The second day, patients receive an adapted conventional scheme: 2 cycles of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 2 cycles of purification (stasis: 110 mn ; volume 1200cc/m²). |
Dialysate samples (8 by scheme, volume of 10 mL) are collected at each cycle (one at the beginning and one at the end of the cycle).
A blood sample (5 mL) is collected at the beginning of the second scheme and a 24-hour urine sample at the end of the second scheme.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Intra-dialytic concentrations of different electrolytes (sodium, phosphorus, urea, creatinine, glucose and proteins)
Time Frame: In a maximum of 72 hours after collection
|
In a maximum of 72 hours after collection
|
Collaborators and Investigators
Investigators
- Principal Investigator: Cécile Courivaud, MCU/PH, Besançon University Hospital, Nephrology Department
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TULIPE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End-stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Sir Mortimer B. Davis - Jewish General HospitalMcGill University Health Centre/Research Institute of the McGill University...Not yet recruitingEnd Stage Renal Disease on Dialysis
-
Suzhou Alphamab Co., Ltd.RecruitingEnd-Stage Renal Disease Requiring HaemodialysisChina
-
Tuen Mun HospitalEnrolling by invitationDialysis Efficiency and Transporter Evaluation Computational Tool in Peritoneal Dialysis (DETECT-PD)Peritoneal Dialysis | End-Stage Kidney Disease | End Stage Renal Disease (ESRD) | End Stage Renal Failure on Dialysis | Peritoneal Dialysis Patients | End Stage Renal Disease on Dialysis (Diagnosis)Hong Kong
-
Iperboreal Pharma SrlWithdrawnEnd-Stage Renal Disease
-
Cubist Pharmaceuticals LLCCompleted
-
Medical University of GrazWithdrawnEnd-stage Renal DiseaseAustria
-
Janssen Research & Development, LLCBayerCompleted
Clinical Trials on comparison of two regimens in peritoneal dialysis
-
University of Alabama at BirminghamTerminatedMycoplasma Genitalium InfectionUnited States
-
Dartmouth-Hitchcock Medical CenterPatient-Centered Outcomes Research Institute; Dartmouth CollegeRecruitingCancer Screening | Pediatric Mental Health Services | Serious IllnessUnited States
-
Chinese University of Hong KongCompletedPeritoneal Dialysis Associated PeritonitisHong Kong
-
Davita Clinical ResearchBaxter Healthcare CorporationTerminatedFunctionally Anuric | Hemodialysis/Peritoneal Dialysis
-
San Gerardo HospitalCompletedInfant, Very Low Birth Weight | Infant Malnutrition | Feeding Disorder of Infancy or Early Childhood | Splanchnic Oximetry | Splanchnic OxygenationItaly
-
Stanford UniversityWithdrawnPeritoneal Dialysis
-
The Netherlands Cancer InstituteErasmus Medical Center; Amsterdam University Medical Centres (AUMC)Active, not recruitingCRC | Advanced NeoplasiaNetherlands
-
Karolinska InstitutetCompletedDialysis Dependent Chronic Kidney Disease | Chronic Renal Failure (CRF)Sweden
-
Karl Landsteiner Insitute for Nephrology and Haemato-OncologyUniversity of Vienna; Karl Landsteiner University of Health Sciences; Medical...CompletedPharmacokinetics | Peritoneal Dialysis-associated Peritonitis | Intravenous | Meropenem | Ciprofloxacin | Peritoneal Dialysis (PD) | Intravenous Administration | Intraperitoneal | Ampicillin | Aztreonam | Minimum Inhibitory Concentration (MIC)Austria
-
The People's Hospital of GaozhouCompletedExploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis SolutionChina